Spectrum Pharmaceuticals Completes $4.44 Million Financing With Institutional Investors Thursday May 8, 8:31 am ET IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has raised $4.44 million through the sale of newly issued shares

Spectrum Pharmaceuticals Receives Nasdaq Notice Tuesday April 8, 7:08 pm ET IRVINE, Calif., April 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the Company received a Nasdaq staff determination indicating that the Company is not in compliance with

Spectrum Pharmaceuticals Reports Fourth Quarter and Year End Financials Monday March 31, 8:01 am ET IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News ) today reported a net loss for the fourth quarter ended December 31, 2002 of $3.8 million, or

Spectrum Pharmaceuticals to Receive $1 Million Investment Investment to Support Accelerated Development of Spectrum's Generic Drug Business Friday February 7, 8:30 am ET IRVINE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has

Spectrum Pharmaceuticals Announces Filing of First ANDA With the FDA for Approval to Market Generic Drugs in the United States Company Plans Additional Filings During 2003; Looks for Revenue From Generic Business During 2004 Wednesday January 15, 8:33 am ET IRVINE, Calif., Jan.

Spectrum Pharmaceuticals Completes Equity Offering Thursday December 19, 9:00 am ET IRVINE, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that it had raised $598,500 from three investors through the sale of 285,000 shares of common stock, at

Spectrum Pharmaceuticals to Expand Study of Superficial Bladder Cancer Drug Wednesday December 11, 2:12 pm ET Complete Response in First Patient Treated Leads Company to Expand the Number of Clinical Sites and Accelerate Enrollment IRVINE, Calif., Dec.

NeoTherapeutics to Change Name to Spectrum Pharmaceuticals Monday December 9, 1:40 pm ET Company Will Host Conference Call to Discuss Name Change, Recent Financings and Plans Going Forward IRVINE, Calif., Dec. 9 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc.

NeoTherapeutics Completes Equity Offering Friday November 22, 1:44 pm ET IRVINE, Calif., Nov. 22 /PRNewswire-FirstCall/ -- NeoTherapeutics Inc. (Nasdaq: NEOT) announced today that it had raised $938,000 through the sale to five investors including Luigi Lenaz, M.D., President of the Company's

NeoTherapeutics Completes Issuance of Shares To Vendors Thursday November 21, 1:55 pm ET IRVINE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- NeoTherapeutics Inc. (Nasdaq: NEOT) announced today that it had issued 356,926 shares of common stock in a private placement to five vendors as payment for

NeoTherapeutics Announces Resignation of Alvin J. Glasky, Ph.D. from the Company's Board of Directors Monday November 18, 10:37 am ET IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/ -- NeoTherapeutics Inc. (Nasdaq: News) announced today that Alvin J. Glasky, Ph.D.

NASDAQ Approves NeoTherapeutics Listing on Small-Cap Market Tuesday October 15, 5:52 pm ET IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) announced today that the Company has met all requirements for listing on the NASDAQ Small-Cap Market and that NASDAQ has

NeoTherapeutics Updates Implementation of Strategy Monday October 7, 9:25 am ET IRVINE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- NeoTherapeutics Inc. (Nasdaq: NEOT) announced progress in the implementation of the strategic plan unveiled on August 20th and provided guidance on the future direction

NeoTherapeutics and GPC Biotech Sign Agreement To Co-Develop Phase 3 Oral Anti-Cancer Drug NeoTherapeutics to receive licensing fees, milestone payments and royalties; GPC Biotech to fully fund development and commercialization costs Tuesday October 1, 2:00 am ET IRVINE, Calif., Oct.

NeoTherapeutics Provides Update on Nasdaq Listing Status Monday September 30, 7:52 pm ET IRVINE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) has filed an application for listing on the Nasdaq small cap exchange. The Company has been notified by Nasdaq that it

NeoTherapeutics Regains Compliance with NASDAQ Minimum Bid Requirement Thursday September 26, 11:54 am ET IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) announced today that NASDAQ has notified the Company that it has regained compliance with NASDAQ's

NeoTherapeutics' Stockholders Approve Reverse Stock Split and Proposal for New Financings Trading on post-split basis to commence September 6, 2002 Thursday September 5, 2:41 pm ET IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/-- NeoTherapeutics Inc. (Nasdaq: NEOT), announced today that its

NeoTherapeutics Announces Organizational Changes Designed to Bring On-Going Monthly Expenses Below $500,000 Changes solidify strategic commitment to anti-cancer drug development and out-licensing of neurology products IRVINE, Calif., Aug. 22 /PRNewswire-FirstCall/-- NeoTherapeutics, Inc.

NeoTherapeutics Announces New Financial Leadership IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT ) announced today the retirement of Samuel Gulko, Senior Vice President, Finance; Chief Financial Officer; Secretary; and, Treasurer. Mr.

NeoTherapeutics Announces Major Strategic Restructuring Company to focus resources on development of phase 3 anti-cancer drug and licensing out anti-psychotic and attention deficit drugs IRVINE, Calif., Aug. 20 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc.